2. Search Result
Search Result
Results for "

contractile force

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-105431
    ASI-222

    		Na+/K+ ATPase Cardiovascular Disease
    ASI-222 is an aminosugar cardiac glycoside. ASI-222 can inhibit Na+/K+ ATPase and show positive inotropic effect. ASI-222 can be used for the research of cardiovascular disease .
    ASI-222
  • HY-B0204B
    (-)-Pimobendan

    (-)-UD-CG115

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    (-)-Pimobedan is an isomer of pimobedan. It has the property of stereoselective partitioning or distribution into erythrocytes. The clearance of (-)-pimobedan from erythrocytes is significantly lower than that of (+)-pimobedan, which is entirely due to its stereoselective distribution into erythrocytes. This stereoselective property of (-)-pimobedan may explain the phenomenon previously reported that it produces a 1.5-fold greater contractile force than the (+)-isomer in detergent-treated myocardial specimens of guinea pigs and dogs. These properties suggest that (-)-pimobedan may have unique advantages in terms of in vivo distribution and pharmacological action, which may have important implications for its clinical use.
    (-)-Pimobendan
  • HY-115381
    Lipoxin A5

    		Endogenous Metabolite Cardiovascular Disease
    Lipoxin A5 is an eicosapentaenoic acid derived from pig white blood cells. Lipoxin A5 slowly contracted the guinea pig lung parenchymal strips with a contractile force similar to that of LXA4 and LXB4.2, but LXA5 did not have the vasodilating effect on the aortic smooth muscle shown by LXA4 and LXB4.2 .
    Lipoxin A5
  • HY-13338A
    (S)-Mabuterol

    		Adrenergic Receptor Cardiovascular Disease
    (S)-Mabuterol is a selective β2 adrenoreceptor agonist that demonstrates blood pressure reduction and increased heart rate and contractile force in animal models.
    (S)-Mabuterol
  • HY-19066
    KW-3407

    		Potassium Channel Cardiovascular Disease
    KW-3407 is an antiarrhythmic agent. KW-3407 can inhibit two-stage (24 and 48 h) coronary ligation-, digitalis- and adrenaline-induced spontaneously occurring arrhythmias with IC50 values of 18.1, 14.4, 18.3 and 21.4 μg/mL. KW-3407 can decrease the sinoatrial rate and contractile force, and increase the coronary blood flow and AV conduction times .
    KW-3407
  • HY-128061
    CDIBA

    		Phospholipase Reactive Oxygen Species (ROS) Inflammation/Immunology
    CDIBA is a cytosolic phospholipase A2 (cPLA2) inhibitor. CDIBA inhibits the activation of cPLA2 in rat diaphragm tissue. CDIBA reduces the level of mitochondrial reactive oxygen species in rat diaphragm tissue after prolonged mechanical ventilation. CDIBA attenuates protein degradation, muscle atrophy and decreased muscle strength in the diaphragm of rats after prolonged mechanical ventilation. CDIBA can be used in studies related to ventilator-induced diaphragmatic dysfunction .
    CDIBA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: